Needham analyst Ami Fadia has reiterated their bullish stance on IMRX stock, giving a Buy rating on September 26.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ami Fadia has given his Buy rating due to a combination of factors that highlight Immuneering’s potential in the market. The recent investor call revealed promising Phase 2a data for atebimetinib, particularly in combination with mGnP for first-line pancreatic ductal adenocarcinoma (PDAC), suggesting a competitive profile compared to the standard of care. The median progression-free survival (mPFS) of 9.6 months for patients, including those with liver metastases, slightly surpasses the mPFS of daraxonrasib in second-line RAS, which stands at 8.1 months.
Moreover, the data indicates that atebimetinib offers superior safety, which could translate into better tolerability for patients. This raises important considerations about whether this greater tolerability might lead to enhanced durability of treatment. Additionally, even if atebimetinib’s efficacy is on par or slightly lower than daraxonrasib, its safety profile might make it a preferred option for first-line treatment, preserving other options for second-line therapy where choices are limited. These factors contribute to the positive outlook and Buy rating for Immuneering’s stock.
According to TipRanks, Fadia is a 5-star analyst with an average return of 13.2% and a 49.89% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Jazz Pharmaceuticals.
In another report released on September 26, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.